EP3897630A4 - THIENOPYRIDINE RIPK2 INHIBITORS - Google Patents

THIENOPYRIDINE RIPK2 INHIBITORS Download PDF

Info

Publication number
EP3897630A4
EP3897630A4 EP19899710.8A EP19899710A EP3897630A4 EP 3897630 A4 EP3897630 A4 EP 3897630A4 EP 19899710 A EP19899710 A EP 19899710A EP 3897630 A4 EP3897630 A4 EP 3897630A4
Authority
EP
European Patent Office
Prior art keywords
thienopyridine
ripk2 inhibitors
ripk2
inhibitors
thienopyridine ripk2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP19899710.8A
Other languages
German (de)
French (fr)
Other versions
EP3897630A1 (en
EP3897630B1 (en
Inventor
Kurt ARMBRUST
Fedor ROMANOV MICHAILIDIS
Karin Irmgard WORM
John Michael Ellis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of EP3897630A1 publication Critical patent/EP3897630A1/en
Publication of EP3897630A4 publication Critical patent/EP3897630A4/en
Application granted granted Critical
Publication of EP3897630B1 publication Critical patent/EP3897630B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP19899710.8A 2018-12-21 2019-12-20 Thienopyridine inhibitors of ripk2 Active EP3897630B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862783742P 2018-12-21 2018-12-21
PCT/US2019/067724 WO2020132384A1 (en) 2018-12-21 2019-12-20 Thienopyridine inhibitors of ripk2

Publications (3)

Publication Number Publication Date
EP3897630A1 EP3897630A1 (en) 2021-10-27
EP3897630A4 true EP3897630A4 (en) 2022-09-07
EP3897630B1 EP3897630B1 (en) 2024-01-10

Family

ID=71098055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19899710.8A Active EP3897630B1 (en) 2018-12-21 2019-12-20 Thienopyridine inhibitors of ripk2

Country Status (9)

Country Link
US (1) US11168093B2 (en)
EP (1) EP3897630B1 (en)
JP (1) JP7458406B2 (en)
KR (1) KR102943035B1 (en)
CN (1) CN113874015B (en)
AR (1) AR117472A1 (en)
ES (1) ES2974634T3 (en)
TW (1) TW202039481A (en)
WO (1) WO2020132384A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
IT202000031778A1 (en) 2020-12-22 2022-06-22 Guala Closures Spa CLOSURE WITH TEAR SEAL
CN114957280B (en) * 2021-12-31 2024-09-17 成都赜灵生物医药科技有限公司 Thiophene [2,3-d] pyrimidine derivatives and uses thereof
WO2025085928A1 (en) 2023-10-20 2025-04-24 Odyssey Therapeutics, Inc. Methods of treating a patient with an inflammatory bowel disease
CN117843656B (en) * 2023-11-13 2026-02-03 四川大学华西医院 Thiophene [3,2-d ] pyrimidine derivative, and preparation method and application thereof
CN119462516B (en) * 2024-10-18 2025-10-14 广东莱佛士制药技术有限公司 A compound of formula I, its preparation method and application, and a preparation method of abemaciclib intermediate compound A

Family Cites Families (200)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4659717A (en) 1985-08-21 1987-04-21 Eli Lilly And Company Dihydropyridines useful in the treatment of angina and stroke
CH681806A5 (en) 1991-03-19 1993-05-28 Ciba Geigy Ag
DE59500788D1 (en) 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative activity
FR2732969B1 (en) 1995-04-14 1997-05-16 Adir NOVEL PYRIDINIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
SI9620103A (en) 1995-07-06 1998-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
WO1998007726A1 (en) 1996-08-23 1998-02-26 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
JP4166296B2 (en) 1997-04-25 2008-10-15 塩野義製薬株式会社 Compound having dopamine receptor antagonistic action
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
EP1028964A1 (en) 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
AU4231299A (en) 1998-06-04 1999-12-20 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
WO2002051849A1 (en) 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
EP1442028A4 (en) 2001-11-06 2009-11-04 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
ATE425753T1 (en) 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc BIARYL COMPOUNDS WITH ANTI-INFECTIVE ACTION
US20050288299A1 (en) 2002-10-09 2005-12-29 Mavunkel Babu J Azaindole derivatives as inhibitors of p38 kinase
AU2003279230A1 (en) 2002-10-09 2004-05-04 Scios Inc. AZAINDOLE DERIVATIVES AS INHIBITORS OF p38 KINASE
AU2003296405A1 (en) 2003-01-06 2004-08-10 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
US7381825B2 (en) 2003-03-17 2008-06-03 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7253166B2 (en) 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
SE0301372D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
DE10337942A1 (en) 2003-08-18 2005-03-17 Merck Patent Gmbh aminobenzimidazole derivatives
JP2005194198A (en) 2003-12-26 2005-07-21 Takeda Chem Ind Ltd Thienopyridine compound
US20050239806A1 (en) 2004-01-13 2005-10-27 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
WO2005080377A1 (en) 2004-02-20 2005-09-01 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGF-β INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
US20050203081A1 (en) 2004-02-25 2005-09-15 Jinbo Lee Inhibitors of protein tyrosine phosphatase 1B
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
JP2008503473A (en) 2004-06-17 2008-02-07 プレキシコン，インコーポレーテッド Compounds that modulate C-KIT activity
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
FR2873694B1 (en) 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si NEW AZA-INDOLES INHIBITORS OF MTP AND APOB
ES2438017T3 (en) 2004-07-30 2014-01-15 Methylgene Inc. VEGF receptor and HGF receptor signaling inhibitors
JP2008508358A (en) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Aryl-amino substituted pyrrolopyrimidine multikinase inhibitor compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8293764B2 (en) 2004-10-19 2012-10-23 The Regents Of The University Of California Compositions and methods for disruption of BRCA2-Rad51 interaction
MX2007004783A (en) 2004-10-21 2007-05-11 Pfizer Inhibitors of hepatitis c virus protease, and compositions and treatments using the same.
EP1817295B1 (en) 2004-11-18 2012-11-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
WO2006092430A1 (en) 2005-03-03 2006-09-08 Universität des Saarlandes Selective inhibitors of human corticosteroid synthases
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
WO2006114180A1 (en) 2005-04-25 2006-11-02 Merck Patent Gmbh Novel aza- heterocycles serving as kinase inhibitors
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
KR101378716B1 (en) 2005-05-20 2014-04-10 메틸진 인코포레이티드 Inhibitors of vegf receptor and hgf receptor signaling
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
KR100546041B1 (en) 2005-05-31 2006-01-26 가야에이엠에이 주식회사 Manufacturing Method of Titanium Carbide Powder Using Rotary Kiln Furnace
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
WO2007028145A2 (en) 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
AR056200A1 (en) 2005-09-27 2007-09-26 Wyeth Corp TIENO [2,3-B] PIRIDIN-5-CARBONITRILS AS INHIBITORS OF PROTEIN KINASE
WO2007064861A2 (en) 2005-12-02 2007-06-07 Brandeis University Asymmetric friedel-crafts alkylations catalyzed by byfunctional cinchona alkaloids
WO2007067537A1 (en) 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
AR060061A1 (en) 2006-03-22 2008-05-21 Methylgene Inc INHIBITORS OF THE ACTIVITY OF PROTEIN TIROSINA QUINASA
WO2007120726A2 (en) 2006-04-11 2007-10-25 The Regents Of The University Of California Compositions and methods related to rad51 inactivation in the treatment of neoplastic diseases, and especially cml
US20100267707A1 (en) 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (en) 2006-07-14 2008-04-25 Amgen Inc FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE
AU2007275221A1 (en) 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
EA201501088A1 (en) 2006-08-08 2017-01-30 Миллениум Фармасьютикалз, Инк. Heteroaryl Compounds Used as E1 Inhibitors Activating Enzymes
AU2007284537B2 (en) 2006-08-17 2012-04-12 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
JP2010507618A (en) 2006-10-27 2010-03-11 グラクソ グループ リミテッド 7-azaindole derivatives as c-Met kinase inhibitors
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US8076350B2 (en) 2006-12-22 2011-12-13 Abbott Laboratories Spirocyclic azaadamantane derivatives and methods of use
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc Small molecule inhibitors of protein arginine methyltransferases (prmts)
KR20100015546A (en) 2007-04-13 2010-02-12 사노피-아벤티스 A transition metal catalyzed synthesis of n-aminoindoles
WO2008135232A1 (en) 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
JP2008308448A (en) 2007-06-15 2008-12-25 Sankyo Agro Kk (3-Sulfur atom substituted phenyl) heteroaryl derivative
DE102007027800A1 (en) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted bicyclic heteroaryl compounds and their use
US20100249030A1 (en) 2007-07-31 2010-09-30 Schering Corporation Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
WO2009027732A1 (en) 2007-08-24 2009-03-05 Astrazeneca Ab 5-6-bicyclic heteroaromatic compounds with antibacterial activity
DE102007048716A1 (en) 2007-10-11 2009-04-23 Merck Patent Gmbh Imidazo [1,2-a] pyrimidine derivatives
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
US20110201599A1 (en) 2008-07-03 2011-08-18 Exelixis, Inc. CDK Modulators
UY31984A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF N-substituted 1- (3,4-difluorobenzyl) -6-oxo-1,6-dihydropyrimidin-5-carboxamides and 2- (3,4-difluorobenzyl) -3-oxo-2,3-dihydro- N-substituted 1H-pyrazol-4-carboxamides.
UY31982A (en) 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
US20110218211A1 (en) 2008-08-16 2011-09-08 Genentech, Inc. Azaindole inhibitors of iap
JP5597200B2 (en) 2008-08-18 2014-10-01 プロメガ コーポレイション Compounds producing luminescence and methods for detecting cytochrome P4503A enzyme
AU2009284695A1 (en) 2008-08-19 2010-02-25 The University Of Sydney Novel compounds and their uses in diagnosis
CN102186479A (en) 2008-09-10 2011-09-14 凯利普西斯公司 Aminopyrimidine inhibitors of histamine receptors for the treatment of disease
US9006252B2 (en) 2008-09-26 2015-04-14 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
ES2599458T3 (en) 2008-10-14 2017-02-01 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
KR100961410B1 (en) 2008-10-14 2010-06-09 (주)네오팜 As protein kinase inhibitors, heterocyclic compounds
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
WO2010061903A1 (en) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pyrimidine derivative and pyridine derivative both having pi3k inhibitory activity
US8765953B2 (en) 2008-12-23 2014-07-01 Aquilus Pharmaceuticals, Inc. Compounds and methods for the treatment of pain and other diseases
KR20100101055A (en) 2009-03-07 2010-09-16 주식회사 메디젠텍 Composition for treating or preventing nuclear export of gsk3- mediated disease including compound for inhibiting nuclear export of gsk3
WO2010107768A1 (en) 2009-03-18 2010-09-23 Schering Corporation Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
JP2012521988A (en) 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Imaging agents for detecting neurological disorders
US9593108B2 (en) 2009-04-06 2017-03-14 Ptc Therapeutics, Inc. Compounds and methods for antiviral treatment
KR101070223B1 (en) 2009-05-14 2011-10-06 덕산하이메탈(주) Chemical comprising arylamino and organic electronic element using the same, terminal thererof
EP2477498A4 (en) 2009-09-14 2013-02-27 Merck Sharp & Dohme DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
US9095596B2 (en) 2009-10-15 2015-08-04 Southern Research Institute Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
WO2011050323A1 (en) 2009-10-22 2011-04-28 The Washington University Compounds and methods for treating bacterial infections
CN102574843B (en) 2009-10-22 2015-06-17 法博太科制药有限公司 Fused ring analogs of antifibrotic agents
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
PL2520575T3 (en) 2009-12-28 2017-05-31 General Incorporated Association Pharma Valley Project Supporting Organization 1,3,4-oxadiazole-2-carboxamide compound
MX2012009377A (en) 2010-02-11 2012-09-12 Univ Vanderbilt BENZISOXAZOLES AND AZABENZISOXAZOLES AS mgluR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION.
UY33304A (en) 2010-04-02 2011-10-31 Amgen Inc HETEROCYCLIC COMPOUNDS AND THEIR USES
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
WO2011149827A1 (en) 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
ES2526124T3 (en) 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. GPR120 receptor agonists and their uses
FR2963268B1 (en) 2010-07-27 2015-03-13 Areva Nc WORKING WHEEL ADVANTAGE DEVICE AND USE THEREOF IN A RECTIFIER WITHOUT A NUCLEAR FUEL PELLET CENTER
DE102010033548A1 (en) 2010-08-05 2012-02-09 Merck Patent Gmbh Materials for electronic devices
US9034895B2 (en) 2010-08-20 2015-05-19 University Of Washington Through Its Center For Commercialization Composition and methods for treating glioblastoma
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
EP2426202A1 (en) 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kinases as targets for anti-diabetic therapy
TW201219401A (en) 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
CN102399233B (en) 2010-09-15 2014-08-13 山东轩竹医药科技有限公司 Dual PI3K and mTOR inhibitor compounds
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
KR101817221B1 (en) 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 Substituted 4-(selenophen-2(or 3)-ylamino)pyrimidine compounds and methods of use thereof
JP5720253B2 (en) 2011-01-06 2015-05-20 コニカミノルタ株式会社 ORGANIC ELECTRONIC ELECTRONIC DEVICE, DISPLAY DEVICE AND LIGHTING DEVICE HAVING THE SAME
US8759386B2 (en) 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
AU2012212323A1 (en) 2011-02-01 2013-09-12 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
RU2013138835A (en) 2011-02-09 2015-03-20 Ф. Хоффманн-Ля Рош Аг HETEROCYCLIC COMPOUNDS AS PI3 KINASE INHIBITORS
WO2012130829A1 (en) 2011-03-29 2012-10-04 Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh New boranophosphate analogues of cyclic nucleotides
KR20120119932A (en) 2011-04-21 2012-11-01 (주)네오팜 Heterocyclic compounds as PI3 kinase inhibitors
US20130072473A1 (en) 2011-05-09 2013-03-21 Proteostasis Therapeutics, Inc. Compounds for treating protein folding disorders
PL2710018T3 (en) 2011-05-19 2022-04-04 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
DE102011111400A1 (en) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclic heteroaromatic compounds
WO2013033981A1 (en) 2011-09-06 2013-03-14 江苏先声药物研究有限公司 2,7-naphthyridine derivative, preparation method therefor and use thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
JP5741373B2 (en) 2011-10-25 2015-07-01 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE
AR090037A1 (en) 2011-11-15 2014-10-15 Xention Ltd DERIVATIVES OF TIENO AND / OR FURO-PYRIMIDINES AND PYRIDINES INHIBITORS OF THE POTASSIUM CHANNELS
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
GB201120993D0 (en) 2011-12-06 2012-01-18 Imp Innovations Ltd Novel compounds and their use in therapy
WO2013085339A2 (en) 2011-12-07 2013-06-13 주식회사 두산 Organic light-emitting compound and organic electroluminescent device using same
JP6126131B2 (en) 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド IRAK inhibitors and uses thereof
SG11201406759YA (en) 2012-04-26 2014-11-27 Bristol Myers Squibb Co Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
WO2013165898A2 (en) 2012-05-01 2013-11-07 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting resolvases
KR101537436B1 (en) 2012-08-17 2015-07-17 주식회사 두산 Novel compound and organic electroluminescent device comprising the same
CN103626783B (en) 2012-08-22 2016-06-08 中国科学院上海药物研究所 Bicyclic fused heterocyclic compound and application and pharmaceutical composition thereof
WO2014055587A1 (en) 2012-10-02 2014-04-10 California Institute Of Techonolgy Transition-metal-free silylation of aromatic compounds
WO2014055586A1 (en) 2012-10-02 2014-04-10 California Institute Of Technology Transition-metal free reductive cleavage of aromatic c-o, c-n, and c-s bonds by activated silanes
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
KR101547623B1 (en) 2012-10-24 2015-08-26 주식회사 두산 Organic electroluminescent device
CN103833753B (en) 2012-11-22 2017-02-01 广东东阳光药业有限公司 Alkynyl compound and its use method and purpose
WO2014079803A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hairloss
WO2014089280A1 (en) 2012-12-07 2014-06-12 Calitor Sciences, Llc Alkynyl compounds and methods of use
CN103012428A (en) 2013-01-08 2013-04-03 中国药科大学 4-(five-membered heterocycle pyrimidin/substituted pyridine) amino-1H-3-pyrazolecarboxamide CDK (cyclin dependent kinase)/Aurora dual inhibitor and application thereof
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
WO2014164543A1 (en) 2013-03-13 2014-10-09 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
CN104119331B (en) 2013-04-26 2018-02-06 广东东阳光药业有限公司 Alkenyl compound and its application method and purposes
EP2988749B1 (en) * 2013-04-26 2019-08-14 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9351494B2 (en) 2013-05-03 2016-05-31 Inscent, Inc. Honeybee repellents and uses thereof
WO2014179785A1 (en) 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
WO2014193647A2 (en) 2013-05-26 2014-12-04 Calitor Sciences, Llc Alkenyl compounds and methods of use
WO2014194245A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Cdk8 inhibitors and uses thereof
WO2014194242A2 (en) 2013-05-31 2014-12-04 Nimbus Iris, Inc. Flt3 inhibitors and uses thereof
EP2818472A1 (en) 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
KR20160060100A (en) 2013-09-22 2016-05-27 칼리토르 사이언시즈, 엘엘씨 Substituted aminopyrimidine compounds and methods of use
EP3055290B1 (en) 2013-10-10 2019-10-02 Araxes Pharma LLC Inhibitors of kras g12c
WO2015055770A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015171833A1 (en) 2014-05-06 2015-11-12 The Regents Of The University Of California Wound healing using braf inhibitors
KR101713530B1 (en) 2014-05-16 2017-03-08 (주)피엔에이치테크 An electroluminescent compound and an electroluminescent device comprising the same
KR101998435B1 (en) 2014-06-09 2019-07-09 주식회사 두산 Organic electro luminescence device
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
EA035646B1 (en) 2014-08-29 2020-07-21 Сиэйчдиай Фаундэйшн, Инк. Probes for imaging huntingtin protein
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
KR101708097B1 (en) 2014-10-22 2017-02-17 주식회사 두산 Organic electro luminescence device
DK3209655T3 (en) 2014-10-24 2020-09-28 Landos Biopharma Inc Lanthionine Synthesis C-like 2-based Therapeutica
CN107454899B (en) * 2014-10-27 2020-05-29 大学健康网络 RIPK2 inhibitors and methods of treating cancer therewith
CN105712998B (en) 2014-12-05 2019-12-13 上海润诺生物科技有限公司 Azaindole derivatives, preparation method and medical application thereof
JP6621477B2 (en) 2014-12-18 2019-12-18 ファイザー・インク Pyrimidine and triazine derivatives and their use as AXL inhibitors
JP6038111B2 (en) 2014-12-27 2016-12-07 ヤマサ醤油株式会社 2,6-Dichloro-8-iodo-7-deazapurine for the synthesis of polysubstituted 7-deazapurine derivatives
WO2016115360A1 (en) 2015-01-14 2016-07-21 Coferon, Inc. C-myc ligands capable of dimerizing in an aqueous solution, and methods of using same
ES2762936T3 (en) 2015-03-12 2020-05-26 Syngenta Participations Ag Tetracyclic derivatives active as pesticides with sulfur-containing substituents
JP6070756B2 (en) 2015-04-15 2017-02-01 コニカミノルタ株式会社 ORGANIC ELECTROLUMINESCENT ELEMENT MATERIAL, ORGANIC ELECTROLUMINESCENT ELEMENT, METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE
US10875833B2 (en) 2015-06-12 2020-12-29 Transitions Optical, Inc. Alignment compounds
MA42456B1 (en) 2015-06-25 2021-06-30 Univ Health Network Hpk1 inhibitors and methods of use
JP2018524337A (en) 2015-07-01 2018-08-30 シンジェンタ パーティシペーションズ アーゲー Tetracyclic derivatives having sulfur-containing substituents and active in pest control
WO2017008826A1 (en) 2015-07-10 2017-01-19 Technische Universitaet Braunschweig New indole compounds having antiprotozoal activity and its use as well as methods for producing the same
DE102015008860A1 (en) 2015-07-14 2017-01-19 Voxeljet Ag Device for adjusting a printhead
US20170010630A1 (en) 2015-07-22 2017-01-12 Boe Technology Group Co., Ltd. Touch Display Screen, Method for Preparing Touch Display Screen and Attaching Adhesive Jig
GB201521767D0 (en) 2015-12-10 2016-01-27 Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R&D Therapeutic agents
AU2016378579A1 (en) 2015-12-22 2018-06-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-MLL interaction
WO2017133664A1 (en) 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Bicyclic pyridine and pyrimidine derivatives and their use in the treatment， amelioration or prevention of influenza
EP3416963B1 (en) 2016-02-17 2021-07-28 Global Blood Therapeutics, Inc. Histone methyltransferase inhibitors
WO2017144341A1 (en) 2016-02-23 2017-08-31 Bayer Cropscience Aktiengesellschaft Condensed bicyclic heterocycle derivatives as pest control agents
CN107151240A (en) 2016-03-04 2017-09-12 中国科学院上海药物研究所 Polysubstituted carbostyril compound of one class and its production and use
BR112018068066B1 (en) 2016-03-11 2023-11-28 Ac Immune Sa Bicyclic compounds and their use, diagnostic and pharmaceutical composition, mixtures, methods of collecting data for diagnosis, to determine a predisposition to, to monitor residual disorder, and to predict the responsiveness of a patient suffering from a disorder or abnormality associated with aggregates of alpha-synuclein, methods for determining the amount of alpha-synuclein aggregates and for preparing a compound, test kit and kit for preparing a radiopharmaceutical preparation
US11332729B2 (en) 2016-08-24 2022-05-17 California Institute Of Technology Engineered synthase for production of tryptophan derivatives and intransigent substrates
AU2017327539B2 (en) * 2016-09-15 2020-12-24 Boehringer Ingelheim International Gmbh Heteroaryl carboxamide compounds as inhibitors of RIPK2
US10138222B2 (en) * 2016-09-15 2018-11-27 Boehringer Ingelheim International Gmbh Substituted benzamides as RIPK2 inhibitors
WO2018213219A1 (en) 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
US20190002460A1 (en) 2017-06-28 2019-01-03 The Regents Of The University Of Michigan Small molecule inhibitors of egfr and pi3k
WO2020132384A1 (en) 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
X. HE ET. AL.: "Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.", ACS MEDICINAL CHEMISTRY LETTERS, vol. 8, no. 10, 27 September 2017 (2017-09-27), pages 1048 - 1053, XP055575920, DOI: 10.1021/acsmedchemlett.7b00258 *

Also Published As

Publication number Publication date
CN113874015A (en) 2021-12-31
JP2022515406A (en) 2022-02-18
KR20210106506A (en) 2021-08-30
JP7458406B2 (en) 2024-03-29
US11168093B2 (en) 2021-11-09
EP3897630A1 (en) 2021-10-27
ES2974634T3 (en) 2024-06-28
KR102943035B1 (en) 2026-03-25
CN113874015B (en) 2024-05-24
AR117472A1 (en) 2021-08-11
EP3897630B1 (en) 2024-01-10
WO2020132384A1 (en) 2020-06-25
TW202039481A (en) 2020-11-01
US20200199148A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
IL283639A (en) kif18a inhibitors
MA54550A (en) KIF18A INHIBITORS
EP4007752C0 (en) KIF18A INHIBITORS
EP4007753C0 (en) KIF18A INHIBITORS
IL269196A (en) New inhibitors
EP3801503A4 (en) SARM1 INHIBITORS
DK3740479T3 (en) DNA-PK INHIBITORS
EP3788042A4 (en) BCL-2 INHIBITORS
DK3612525T3 (en) PD-1- / PD-L1 INHIBITORS
EP3541932A4 (en) CRISPR-CAS9 INHIBITORS
MA52813A (en) SARM1 INHIBITORS
DK3571192T3 (en) JAK1-SELECTIVE INHIBITORS
DK3681884T3 (en) RAD51 INHIBITORS
IL269602B (en) Freezing method
EP3897630A4 (en) THIENOPYRIDINE RIPK2 INHIBITORS
EP3817736A4 (en) PIKFYVE INHIBITORS
EP3801499A4 (en) MRSA1 INHIBITORS
EP3313828A4 (en) METALLO-BETA-LACTAMASES INHIBITORS
EP3980011C0 (en) SARM1 INHIBITORS
DK3630744T3 (en) PYRAZOLE-MAGL INHIBITORS
MA43367A (en) METALLO-BETA-LACTAMASES INHIBITORS
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors
EP3768272A4 (en) JAK INHIBITORS
MA51611A (en) PI4KIIIBETA INHIBITORS
EP3600301A4 (en) KDM4 INHIBITORS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063198

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20220808

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 495/04 20060101ALI20220802BHEP

Ipc: C07D 417/12 20060101ALI20220802BHEP

Ipc: A61K 31/428 20060101ALI20220802BHEP

Ipc: A61K 31/4365 20060101AFI20220802BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230802

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20231204

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602019045068

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP4 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: CELGENE CORPORATION

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240110

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1648358

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2974634

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240410

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240410

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240411

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602019045068

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20241011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20241220

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251028

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251030

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20251121

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251110

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260114

Year of fee payment: 7